News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
402,899 Results
Type
Article (23805)
Company Profile (163)
Press Release (378931)
Section
Business (115441)
Career Advice (671)
Deals (19042)
Drug Delivery (72)
Drug Development (47719)
Employer Resources (82)
FDA (11268)
Job Trends (9970)
News (196192)
Policy (17726)
Tag
Academia (2090)
Alliances (34035)
Alzheimer's disease (843)
Approvals (11268)
Artificial intelligence (122)
Bankruptcy (110)
Best Places to Work (8538)
Biotechnology (107)
Breast cancer (144)
Cancer (1078)
Cardiovascular disease (82)
Career advice (556)
CAR-T (73)
Cell therapy (214)
Clinical research (39172)
Collaboration (419)
COVID-19 (1839)
C-suite (87)
Data (1038)
Diabetes (101)
Diagnostics (4224)
Earnings (37291)
Employer resources (73)
Events (59497)
Executive appointments (309)
FDA (11791)
Funding (343)
Gene therapy (131)
GLP-1 (365)
Government (2720)
Healthcare (13614)
Infectious disease (1907)
Inflammatory bowel disease (75)
Interviews (94)
IPO (7996)
Job creations (1812)
Job search strategy (511)
Layoffs (188)
Legal (3222)
Lung cancer (169)
Lymphoma (78)
Manufacturing (171)
Medical device (10382)
Medtech (10385)
Mergers & acquisitions (11257)
Metabolic disorders (251)
Neuroscience (1031)
NextGen Class of 2024 (4501)
Non-profit (3510)
Northern California (994)
Obesity (135)
Opinion (121)
Patents (88)
People (34809)
Phase I (11784)
Phase II (16992)
Phase III (13618)
Pipeline (343)
Policy (69)
Postmarket research (1468)
Preclinical (3917)
Radiopharmaceuticals (194)
Rare diseases (176)
Real estate (4413)
Regulatory (12807)
Research institute (1918)
Resumes & cover letters (94)
Southern California (878)
Startups (2316)
United States (9975)
Vaccines (413)
Weight loss (90)
Date
Last 7 days (125)
Last 30 days (1471)
Last 365 days (23927)
2024 (23926)
2023 (26232)
2022 (34782)
2021 (36468)
2020 (35317)
2019 (32542)
2018 (24693)
2017 (21001)
2016 (20282)
2015 (22973)
2014 (16505)
2013 (13552)
2012 (14569)
2011 (14720)
2010 (12419)
Location
Africa (379)
Arizona (89)
Asia (31922)
Australia (3194)
California (2279)
Canada (896)
China (323)
Colorado (120)
Connecticut (130)
Europe (55926)
Florida (347)
Georgia (109)
Illinois (303)
Indiana (178)
Maryland (469)
Massachusetts (1821)
Michigan (117)
Minnesota (215)
New Jersey (845)
New York (776)
North Carolina (535)
Northern California (994)
Ohio (113)
Pennsylvania (587)
South America (567)
Southern California (878)
Texas (363)
Washington State (186)
402,899 Results for "astrazeneca innovation center china".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Podcast
AbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, More
A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an investigation into China exec, the Huntington’s pipeline builds momentum and layoffs continue with Sana Biotechnology and 23andMe.
November 13, 2024
·
1 min read
·
Heather McKenzie
China
AstraZeneca’s Stock Price Takes a Hit as China Chief Investigated for Insurance Fraud
BMO Capital Markets analyst Etzer Darout in a note to investors said the insurance fraud probe represents a “headline risk” to AstraZeneca, but contends that the share selloff is “overdone” and likely a knee-jerk reaction by investors.
November 6, 2024
·
2 min read
·
Tristan Manalac
China
AstraZeneca Names New International Operations Lead Amid Probe on China Exec
Iskra Reic will continue to serve as the pharma’s senior vice president for Vaccines and Immune Therapies as she steps in for Leon Wang, who was detained by Chinese authorities in November.
December 5, 2024
·
3 min read
·
Tristan Manalac
Earnings
AstraZeneca Dodges China Questions While Raising 2024 Outlook With Strong Q3 Sales
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the “important” U.S. market.
November 12, 2024
·
3 min read
·
Kate Goodwin
Prostate cancer
AstraZeneca’s Truqap Redeems Itself with Phase III Prostate Cancer Win
Truqap’s positive clinical data comes after it failed a late-stage study in metastatic triple-negative breast cancer. It helps AstraZeneca position itself as a top player in the prostate cancer space, alongside its Big Pharma colleagues.
November 26, 2024
·
2 min read
·
Tristan Manalac
Pharm Country
Yiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, and Innovative Therapeutics through a Systems Biology Approach
Yiviva, a clinical-stage, platform biotechnology company developing systems biology medicines to treat aging-related diseases, signed a memorandum of understanding with AstraZeneca China to establish a research and development collaboration at AstraZeneca’s Innovation Campus in Chengdu, China.
February 5, 2024
·
4 min read
Policy
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
FibroGen, Inc. announced that FibroGen and AstraZeneca have agreed to terminate the U.S./RoW roxadustat collaboration agreement entered into on July 30, 2013, under which AstraZeneca held development and commercialization rights in the United States and other territories outside of China not licensed to Astellas Pharma Inc.
February 26, 2024
·
4 min read
Diabetes
Innovent’s Lilly-Partnered Type 2 Diabetes Drug Aces Phase III in China, Inches Closer to Approval
Innovent Biologics’ dual GLP-1/glucagon receptor agonist mazdutide is also being developed for chronic weight management. China’s regulator accepted Innovent’s drug application for this indication in February 2024.
July 22, 2024
·
2 min read
·
Tristan Manalac
Cardiovascular disease
AstraZeneca Puts $2B On The Line for Preclinical Heart Disease Drug
For an exclusive license to the preclinical Lp(a) disruptor, AstraZeneca is paying CSPC Pharmaceutical Group $100 million upfront and offering up to $1.92 billion in regulatory and commercial milestones.
October 7, 2024
·
2 min read
·
Tristan Manalac
Cancer
AstraZeneca/Daiichi Sankyo, BioNTech, Merus to Present Promising Cancer Therapies at ESMO Asia 2024
At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus will reveal promising mid-stage data for their respective cancer candidates.
December 2, 2024
·
4 min read
·
Tristan Manalac
1 of 40,290
Next
